Please ensure Javascript is enabled for purposes of website accessibility
Cory Renauer

Cory Renauer


Cory is a long-term minded analyst focused on the Healthcare Sector. He genuinely enjoys cutting through the complexity to help everyday investors make better decisions.

Recent articles


Here's Why Sigilon Therapeutics Stock Is Tanking Today

A clinical hold for the company's lead candidate wasn't what investors wanted to hear this morning.


Here's Why Biohaven Pharmaceutical Is Soaring Today

Preliminary sales figures for the company's new migraine drug were much better than expected.


Is Eli Lilly a Better Alzheimer's Stock Than Biogen?

An unusually lenient FDA is a knife that cuts both ways for Biogen.


Here's Why Provention Bio Stock Is Diving Today

The company's latest letter from the FDA wasn't what investors had hoped for.


Here's What's Pushing Cerevel Therapeutics Stock Lower Today

Investors aren't thrilled about how this biotech intends to pay operating expenses that are about to balloon.


Here's What Drove These Stocks Higher This Week

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.


Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today

A paused clinical trial with an important asset wasn't what investors wanted to hear today.


Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today

Another interim analysis has come and gone with an unsatisfying result.


5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.


Can Intellia Therapeutics Turn Exciting Trial Results into Profits?

New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?


Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today

Positive topline results from the company's schizophrenia candidate were better than expected.


Here's Why Exelixis Stock Is Dropping Today

The company reported successful clinical trial results, but investors were still disappointed.


Can Atossa Therapeutics Stock Keep Climbing?

Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.


Here's Why BioXcel Therapeutics Stock Got Hammered This Week

Investors weren't happy about a secondary share offering.


Why Arcus Biosciences' Big Reveal Wasn't Very Exciting

No news from Arcus Biosciences is bad news for the company and other industry heavyweights.


Here's Why Arcus Biosciences Stock Is Rising Today

Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.


Here's Why Patterson Companies Stock Is Sliding Today

Management's uninspiring outlook for fiscal 2022 was not what investors wanted to hear.


Is It Too Late to Buy Citius Pharmaceuticals Stock?

See if this biotech has what takes to climb even higher.


3 Biotech Stocks With Big Catalysts in June

Important events on the horizon could push these biotech stocks higher or press them further into the dirt.


Here's Why Sage Therapeutics Tanked This Week

The neuroscience-focused biotech company didn't give investors the result they wanted.